About pacritinib
JAK2 and IRAK1 inhibitor
Used for
- Treats adults with intermediate- or high-risk myelofibrosis and platelet counts below 50,000/µL.
Usual adult dose
200 mg by mouth twice daily, with or without food.
Common side effects
- Diarrhea
- Nausea and vomiting
- Low platelet or red blood cell counts
- Bleeding
Important warnings
- Can cause serious bleeding, including fatal bleeding.
- May cause serious infections; assess for infection before and during treatment.
- Can prolong the QT interval and cause abnormal heart rhythms.
- May cause serious heart-related events or blood clots.
Pregnancy
May harm an unborn baby; avoid pregnancy during treatment and for at least one month afterward.
Breastfeeding
Do not breastfeed during treatment and for at least two weeks after the last dose.
Interactions
- Strong CYP3A4 inhibitors can increase pacritinib levels; avoid combination.
- Strong CYP3A4 inducers can reduce pacritinib levels; avoid combination.
- May increase exposure to medicines that are CYP1A2 substrates.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.